Phaseline

Companies › Parvus Therapeutics

Parvus Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PVT401
pMHC-peptide nanomedicine: iron oxide nanoparticle core surrounded by dextran linked to mu
HLA-DRPhase 1Inflammatory Bowel Disease (IBD)Nov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07423000PVT401Phase 1Inflammatory Bowel Disease (IBD)ImmunologyNov 2027

Targets

HLA-DR (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.